194 related articles for article (PubMed ID: 12041526)
21. Caspofungin versus liposomal amphotericin B for empirical therapy.
Tattevin P; Bareau B; Camus C
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
[No Abstract] [Full Text] [Related]
22. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
23. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
Pagano L; Valentini CG; Fianchi L; Caira M
J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
[TBL] [Abstract][Full Text] [Related]
24. [The future of antifungal agents].
Maesaki S
Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
[No Abstract] [Full Text] [Related]
25. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
26. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
[TBL] [Abstract][Full Text] [Related]
27. Empirical antifungal therapy for persistent fever in patients with neutropenia.
Chandrasekar PH
Clin Infect Dis; 2001 Jan; 32(2):320-1. PubMed ID: 11170928
[No Abstract] [Full Text] [Related]
28. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
[TBL] [Abstract][Full Text] [Related]
29. A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment.
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Mahi L; Deray G
Nephrol Dial Transplant; 2007 Oct; 22(10):3090-1. PubMed ID: 17595189
[No Abstract] [Full Text] [Related]
30. Breakthrough invasive pulmonary aspergillosis despite empirical voriconazole therapy for febrile neutropenia: case report and review of the literature.
Meyer M; Waldvogel S; Chalandon Y; Bongiovanni M; Pache JC; Van Delden C
Scand J Infect Dis; 2007; 39(8):731-3. PubMed ID: 17654353
[TBL] [Abstract][Full Text] [Related]
31. Liposomal amphotericin B for fever and neutropenia.
Winston DJ; Schiller GJ; Territo MC
N Engl J Med; 1999 Oct; 341(15):1154-5. PubMed ID: 10515755
[No Abstract] [Full Text] [Related]
32. Liposomal amphotericin B for fever and neutropenia.
Rakita R
N Engl J Med; 1999 Oct; 341(15):1153-4; author reply 1154-5. PubMed ID: 10515754
[No Abstract] [Full Text] [Related]
33. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
Frothingham R
Clin Infect Dis; 2002 Oct; 35(7):896-7; author reply 897-8. PubMed ID: 12228830
[No Abstract] [Full Text] [Related]
34. Voriconazole versus amphotericin B for invasive aspergillosis.
Karthaus M
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12494937
[No Abstract] [Full Text] [Related]
35. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia.
Oren I
Clin Infect Dis; 2005 Mar; 40(5):770-1. PubMed ID: 15714432
[No Abstract] [Full Text] [Related]
36. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
[TBL] [Abstract][Full Text] [Related]
37. [Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia].
Badia X; Roset M; Carreras E; Ausin I; Herrera L
Med Clin (Barc); 2004 May; 122(16):610-6. PubMed ID: 15142508
[TBL] [Abstract][Full Text] [Related]
38. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole.
Panicker J; Walsh T; Kamani N
Pediatr Infect Dis J; 2006 Apr; 25(4):377-9. PubMed ID: 16567998
[TBL] [Abstract][Full Text] [Related]
39. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
40. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
